Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Safety and Bioefficacy of Vitamin D2 and Vitamin D3

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01503216
Recruitment Status : Completed
First Posted : January 2, 2012
Last Update Posted : October 10, 2012
Information provided by (Responsible Party):
Ulrike Lehmann, Martin-Luther-Universität Halle-Wittenberg

Brief Summary:
The aim of this study is to investigate the bioavailability of vitamin D2 and D3 as measured by the increase of the specific hydroxy forms in serum (25(OH)D2 and 25(OH)D3, respectively, and by total 25(OH)D.

Condition or disease Intervention/treatment Phase
Vitamin D Deficiency Dietary Supplement: cholecalciferol Dietary Supplement: ergocalciferol Dietary Supplement: Placebo Not Applicable

Detailed Description:

Study design: Human volunteers will receive supplements containing either vitamin D2 or D3 for a period of 8 weeks. At baseline, after 4 weeks and after 8 weeks, 25(OH)D2, 25(OH)D3 and total 25(OH)D will be measured in serum as the main outcome variables. Additional outcome variables are the Ca concentration in serum, PTH concentration in serum, ambulatory blood pressure and heart rate, and renin expression in peripheral mononuclear cells.

Groups/Cohorts Assigned Interventions

  1. Placebo group
  2. Vitamin D2-group Daily treatment with vitamin d2-supplements (containing 2000 IU per capsule)
  3. Vitamin D3-group Daily treatment with vitamin d3-supplements (containing 2000 IU per capsule)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Health Services Research
Official Title: Safety and Bioefficacy of Vitamin D2 and Vitamin D3: Randomized Trial With Human Volunteers
Study Start Date : January 2012
Actual Primary Completion Date : May 2012
Actual Study Completion Date : May 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitamin D

Arm Intervention/treatment
Experimental: cholecalciferol
Human volunteers receiving cholecalciferol (vitamin D3) for 8 weeks
Dietary Supplement: cholecalciferol
cholecalciferol, 2000 IU per day, 8 weeks
Other Name: Cholecalciferol, vitamin D3

Experimental: Ergocalciferol
Ergocalciferol 2000 IU per day for 8 weeks
Dietary Supplement: ergocalciferol
vitamin d2, 2000 IU per day for 8 weeks

Placebo Comparator: Placebo
Placebo for 8 weeks
Dietary Supplement: Placebo

Primary Outcome Measures :
  1. change of 25-hydroxvitamin D [ Time Frame: after 4 and 8 weeks of supplementation ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 18 years
  • healthy

Exclusion Criteria:

  • supplementation of vitamin d and calcium
  • hypercalcemia
  • hypercalciuria
  • chronical illness (diabetes, kidney diseases, cardiovascular diseases)
  • serum-creatinine above 115 mmol/l
  • pregnancy or breastfeeding women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01503216

Sponsors and Collaborators
Ulrike Lehmann
Layout table for investigator information
Study Director: Jutta Dierkes, Prof. Dr. Institut für Agrar- und Ernährungswissenschaften
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ulrike Lehmann, Principal Investigator, Martin-Luther-Universität Halle-Wittenberg Identifier: NCT01503216    
Other Study ID Numbers: BMBF 0315668A
First Posted: January 2, 2012    Key Record Dates
Last Update Posted: October 10, 2012
Last Verified: October 2012
Keywords provided by Ulrike Lehmann, Martin-Luther-Universität Halle-Wittenberg:
randomized controlled trial
vitamin D
Additional relevant MeSH terms:
Layout table for MeSH terms
Vitamin D Deficiency
Deficiency Diseases
Nutrition Disorders
Vitamin D
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents